VisionWave Holdings, Inc.
VWAVDrugs in Pipeline
13
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How VWAV's past catalysts played out
ACU-4429
Geographic Atrophy
rebamipide 2% ophthalmic suspension
Dry Eye Syndromes
Netarsudil Ophthalmic Solution
Fuchs Endothelial Dystrophy
Emixustat
Stargardt Disease
Riboflavin
Keratoconus
emixustat hydrochloride
Proliferative Diabetic Retinopathy
OPA-6566
Primary Open-angle Glaucoma
GB-102
Diabetic Macular Edema
SHJ002
Myopia, Progressive
Prednisolone acetate
Fuchs' Dystrophy
Drug: GB-102
Neovascular Age-Related Macular Degeneration
SHJ002/Vehicle
Dry Eye Disease
EV06 Ophthalmic Solution
Presbyopia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACU-4429 | Phase 3 | Geographic Atrophy | - | - |
rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndromes | - | - |
Netarsudil Ophthalmic Solution | Phase 3 | Fuchs Endothelial Dystrophy | - | - |
Emixustat | Phase 3 | Stargardt Disease | - | - |
Riboflavin | Phase 2 | Keratoconus | - | - |
emixustat hydrochloride | Phase 2 | Proliferative Diabetic Retinopathy | - | - |
OPA-6566 | Phase 2 | Primary Open-angle Glaucoma | - | - |
GB-102 | Phase 2 | Diabetic Macular Edema | - | - |
SHJ002 | Phase 2 | Myopia, Progressive | - | - |
Prednisolone acetate | Phase 2 | Fuchs' Dystrophy | - | - |
Drug: GB-102 | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
SHJ002/Vehicle | Phase 2 | Dry Eye Disease | - | - |
EV06 Ophthalmic Solution | Phase 2 | Presbyopia | - | - |
Frequently asked questions
What is in VisionWave Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 13 drug candidates in VisionWave Holdings, Inc.'s (VWAV) pipeline across Phase 3, Phase 2. Its lead program is ACU-4429 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VisionWave Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VisionWave Holdings, Inc. (VWAV) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VWAV biotech catalysts?→
Add VWAV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VisionWave Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.